We want to clarify and demystify this process of pharmacovigilance aggregate reporting as much as possible. Let’s start from the very basics and go all the way into the nitty-gritty details.

Japan is at the bottom of the bracket when it comes to preparedness of utilization of electronic health records (EHR). But let’s face it – it is not the only country where the adoption of new technologies in healthcare is inadequately slow. Have you ever wondered what kind of bizarre situations this actually brings?

Have you ever been looking for metrics on how to correctly assess PV providers? Did you ever stop and think about why PV companies exist and what they’re meant to do? Our new series is going to answer some of those questions and perhaps raise more.

This blog post describes activities that could be, we hope in theory, performed to completely cripple the global pharmacovigilance (PV) system and to contaminate global safety databases preventing any kind of reliable assessment of a safety-benefit profile.